Skip to main content

Table 3 Correlation between statin therapy and the prevalence of CSVD at baseline in the cohort study

From: Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age

 

Beta

Wald

OR (95% CI)

P value

Prevalence of Fazekas scale ≥2

 Model 1

−0.783

4.833

0.457 (0.227, 0.919)

0.028

 Model 2

−0.734

4.478

0.480 (0.243, 0.947)

0.034

 Model 3

−0.734

4.501

0.480 (0.244, 0.946)

0.034

Prevalence of lacunes

 Model 1

−0.917

5.533

0.400 (0.186, 0.858)

0.019

 Model 2

−0.842

4.820

0.431 (0.203, 0.914)

0.028

 Model 3

−0.806

4.449

0.447 (0.211, 0.945)

0.035

Prevalence ofVirchow-Robin spaces

 Model 1

−0.614

4.305

0.541 (0.296, 0.990)

0.038

 Model 2

−0.592

3.916

0.553 (0.307, 0.994)

0.045

 Model 3

−0.578

3.581

0.561 (0.315, 0.999)

0.048

Prevalence of microbleeds

 Model 1

0.066

0.037

1.069 (0.544, 2.100)

0.847

 Model 2

0.059

0.027

1.060 (0.528, 2.218)

0.869

 Model 3

0.017

0.002

1.017 (0.516, 2.007)

0.960

  1. Model 1: Adjusted for age and sex
  2. Model 2: model 1 + smoking, alcohol intake, history of hypertension, diabetes, and dyslipidemia; medication for hypertension, diabetes, and platelet aggregation
  3. Model 3: model 2 + body mass index, blood pressure, fasting blood glucose, and blood lipids
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us